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PI3K/AKT/mTOR pathway is one of the most important signaling pathways involved in 
normal cellular processes. Its aberrant activation modulates autophagy, epithelial-
mesenchymal transition, apoptosis, chemoresistance, and metastasis in many human cancers. 
Emerging evidence demonstrates that some infections as well as epigenetic regulatory 
mechanisms can control PI3K/AKT/mTOR signaling pathway. In this review, we focused on 
the role of this pathway in gastric cancer development, prognosis, and metastasis, with an 
emphasis on epigenetic alterations including DNA methylation, histone modifications, and 
post-transcriptional modulations through non-coding RNAs fluctuations as well as H. pylori 
and Epstein-Barr virus infections. Finally, we reviewed different molecular targets and 
therapeutic agents in clinical trials as a potential strategy for gastric cancer treatment through 
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PI3K/AKT/mTOR pathway exerts a vast number of functions in different diseases and cancer 
progression [1, 2]. It is implicated in apoptosis, autophagy, and survival of many types of 
cancer including gastric cancer (GC) [1, 3, 4]. The GENEOM study has shown that single 
nucleotide polymorphisms (SNPs) of the PI3K-AKT-mTOR pathway are associated with 
distant metastasis [5]. Also, PI3K/AKT/mTOR pathway plays a critical role in the promotion 
of cell survival via inhibition of apoptosis-related genes such as  BCL2 associated agonist of 
cell death (BAD), BCL2 associated X (BAX), caspase-9, glycogen synthase kinase 3 (GSK-3), 
and forkhead box protein O1 (FOXO1), and promotion of anti-apoptotic proteins such as NF-
κB and cAMP response element-binding protein (CREB) protein [6, 7]. Moreover, the 
PI3K/AKT/mTOR pathway is a major negative regulator of autophagy [8]. Activation of this 
pathway through activation of the mammalian target of rapamycin (mTOR) can promote cell 
proliferation by inhibiting autophagy. mTOR can suppress the initiation of autophagy through 
phosphorylation of unc-51-like autophagy activating kinase 1 (ULK1) complex subunits [9]. 
mTOR suppression induces autophagy by upregulating autophagy markers such as 
microtubule-associated protein 1A/1B-light chain 3-II (LC3-II), autophagy-related 3 (ATG3), 
and ATG5 as well as downregulating p62 [10, 11]. Additionally, PI3K/AKT signaling is of 
crucial importance for chemoresistance, and contributes to epithelial-mesenchymal transition 
(EMT) which occurs in drug-resistant and metastatic human cancer cells [12-14]. Mounting 
evidence has shown so far the implication of epigenetic mechanisms in the development of 
multidrug resistance (MDR). The impact of several non-coding RNAs on anticancer drugs 
and chemotherapy resistance through modulating the expression of the cancer-related genes 
has been confirmed. Relatively, some micro RNAs (miRNAs) showed different expression 
pattern between GC chemoresistant cell lines and controls, and can therefore be involved in 
chemotherapy resistance [15, 16]. Growing body of evidence has displayed the mechanisms 
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of epigenetic regulation of PI3K/AKT pathway in GC [17, 18]. GC is considered to be the 
third leading cause of cancer-related death worldwide. Epigenetic alterations in tumor 
suppressor genes (TSGs) that control this pathway exert a central role in controlling the 
activity of this pathway [19, 20]. Histone modification, DNA methylation, and non-coding 
RNAs are three main epigenetic players that act on PI3K-AKT-mTOR pathway, and have 
been associated with cell invasion, autophagy, and apoptosis regulation in GC.  
Pathway description  
PI3K, discovered by Lewis Cantley and colleagues [21], participates in the signaling network 
in response to different growth factors. PI3Ks are a family of intracellular enzymes that 
phosphorylate the 3-OH group of inositol ring in phosphatidylinositol membrane lipid. They 
are divided into three classes: I, II, and III based on the regulation of the signaling pathway 
and structure. Class I that has been shown to be more related to cancer is further categorized 
into class IA and IB. They are heterodimeric kinases with regulatory and catalytic subunits. 
The catalytic subunit of class IA PI3K, p110, has four isoforms α, β, γ, and δ that are encoded 
by PIK3CA, PIK3CB, PIK3CG, and PIK3CD genes, respectively. The variants of PI3K 
regulatory subunits include p85α, p85β, and p55γ. Table 1 shows the genes and related 
products of different classes of PI3K proteins and their subunits. [22-26]  
Classes II and III of PI3Ks have a role in the regulation of clathrin-mediated vesicle 
trafficking [27-30], autophagy, and mTOR activation [31, 32]. In addition, PI3Ks have been 
found to present not only a catalytic activity, but they may also be present as scaffolding 
proteins. In the nucleus, PI3Kb was shown to regulate DNA duplication through kinase-
dependent and scaffolding functions [33].  Also, p85a, as a most highly expressed regulatory 
subunit, controls mammalian cytokinesis through its scaffolding function [34]. Furthermore, 
PI3Kγ via kinase-independent scaffolding function plays a critical role in the cardiovascular 
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system [35]. However, PI3Kγ acts as a scaffold not only in the cardiovascular system, but 
also in platelets, endothelial progenitors, and neurons [36-38]. 
The PI3K/AKT/mTOR intracellular signaling pathway is critical for many different cellular 
functions including proliferation, cell growth, survival, differentiation, motility, and 
intracellular trafficking [39]. Activation of PI3K can occur through the binding of a variety of 
ligands including platelet-derived growth factor (PDGF), epidermal growth factor (EGF), 
insulin-like growth factor (IGF), and other growth factors to the receptor tyrosine kinases. 
Activated PI3K then phosphorylates PIP2 to produce PIP3 (Figure 1). The phosphorylated 
inositol rings of phosphoinositides provide docking sites for several PH domain-containing 
signaling proteins such as the serine/threonine (ser/thr) kinases, protein kinase B (PKB that is 
more commonly known as AKT), and phosphoinositide-dependent protein kinase-1 (PDK1). 
Recruitment of PDK1 to the plasma membrane, and to close proximity of PKB causes 
phosphorylation and activation of ser/thr AKT kinase. Three isoforms of AKT including 
AKT1, AKT2, and AKT3 have been identified. PDK1 phosphorylates the amino acid 
threonine at position 308 of AKT kinase. While phosphorylation by PDK1 is essential, it is 
not sufficient for the activation of AKT protein. AKT activation also depends on 
phosphorylation by a second kinase called mTOR, on ser473. mTOR is also a ser/thr protein 
kinase with a molecular weight of 289 kDa which acts as part of two complexes called 
mTORC1 and mTORC2. While mTORC2 phosphorylates AKT at ser473 and activates this 
protein kinase, mTORC1 up-regulates protein synthesis by phosphorylating eukaryotic 
translation initiation factor 4E binding protein (EIF4EBP1) and releasing eukaryotic 
translation initiation factor 4E (eIF4E) that exists as both a free form and as part of the eIF4F 
pre-initiation complex. EIF4E binds to eIF4G and participates in cap related translation 
initiation. EIF4EBP1 directly interacts with eIF4E, and represses its activity by preventing 
the pre-initiation complex assembly with eIF4F, and inhibits translation. On the other hand, 
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mTOR phosphorylates and activates ribosomal S6 kinase family RPS6KB1and RPS6KB2. 
The kinase activity of these proteins leads to an increase in protein synthesis [39]. 
PI3K/AKT/mTOR signaling pathway is regulated by phosphatase and tensin homolog 
(PTEN) protein that acts as a phosphatase to dephosphorylate phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) and results in suppressing PI3K/AKT signaling pathway. Therefore, 
mutations that occur in PTEN may cause neurological deficits, Cowden-syndrome, and many 
types of cancer [40].  
 
Role of PI3K pathway in gastric cancer development 
Evasion from apoptosis and unlimited proliferation are among the main hallmarks of cancer, 
and occur through different mechanisms in cancer cells. AKT regulates cell survival and 
inhibits apoptosis by phosphorylating several components that participate in cell death 
program such as pro-apoptotic BAD, mouse double minute 2 homolog (MDM2), and caspase 
9. Phosphorylation of BAD inhibits its heterodimerization with survival factor B-cell 
lymphoma-extra-large (Bcl-xl), and restores Bcl-xl’s antiapoptotic function [41]. MDM2 acts 
as an oncogene that binds to tumor suppressor p53 and promotes its degradation via the 
proteasome. MDM2 phosphorylation by AKT facilitates its translocation into the nucleus and 
enhances p53 degradation [28, 42]. Besides, caspase-9 phosphorylation by AKT inhibits 
caspase-9 catalytic function, leading to its inactivation and prevention of apoptosis [43]. AKT 
also prevents cell cycle arrest by blocking FOXO mediated transcription of many proteins 
such as Fas ligand (FASL), p27, and p21 [44, 45]. PI3K/AKT/mTOR signaling pathway is 
important in metastasis induction as well as EMT. During EMT epithelial cells show a 
character shift and become less adhesive and more migratory. E-cadherin downregulation is a 
hallmark of EMT. E-cadherin is mainly involved in cell-cell adhesion and helps binding 
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epithelial cells together through adherens junctions. EMT may often accompany and enable 
the invasion by carcinoma cells into adjacent normal tissues [46]. Metastasis is a multistep 
process including a reduction in cell adhesion, cell penetration into the local tissues and 
vessels, movement through circulation, avoidance of immune surveillance, leaving the 
vessels, and finally establishing new cellular colonies at distant sites. AKT plays an important 
role in metastasis and invasion in many types of cancer because of its high expression in 
distant metastasis and lymph node metastasis in comparison with the primary tumor [47]. 
There are many studies on GC cell lines investigating metastasis mechanisms [48-50]. 
PI3K/AKT/mTOR signaling pathway via cooperating with other signaling pathways like 
TGF-β, NF-κβ, Wnt/β catenin and expression transcription factors can affect EMT, 
metastasis, and invasion. Relatively, twist is a transcription factor involved in cell lineage 
determination and differentiation that can induce EMT through increasing the expression of 
N-cadherin, B lymphoma Mo-MLV insertion region 1 homolog (BMI1), AKT2, and Y-box 
binding protein-1 (YB-1). Twist expression is increased by AKT, and the silencing of AKT 
reduces the effect of twist transcription factor [12]. Fluctuations of twist expression are 
common in metastatic carcinomas [51].  A decrease in the 5-year survival of cancerous 
patients with twist upregulation confirmed that twist can be useful as a marker in the 
prognosis of GC [52, 53]. Regulation of twist phosphorylation by AKT promotes the 
transcription of TGF-β and activation of the TGF-β signaling pathway [12]. Snail and slug 
are the other transcription factors that bind to the E cadherin promoter and inhibit its 
expression. They increase the expression of fibronectin, matrix metallopeptidase 9 (MMP-9), 
MMP-2, β catenin, and vimentin, thereby triggering the EMT process [54, 55]. AKT 
upregulates the expression of snail and slug transcription factors by phosphorylating GSK3β 
and facilitating its ubiquitination and degradation. Therefore, AKT prevents further 
degradation of these transcription factors mediated by GSK3β [12]. Activation of NF-κβ by 
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PI3K/AKT also induces the expression of snail, downregulation of E-cadherin, and causes 
EMT progression and metastasis development [56, 57]. PI3K/AKT/mTOR signaling pathway 
exerts an important role in autophagy. Autophagy is a process of self-digestion that is 
programmed to respond to some developmental conditions, nutrient starvation, and stress 
[58]. There are several forms of autophagy including microautophagy, chaperone-mediated 
autophagy, mitophagy, lipophagy, and macroautophagy. Macroautophagy, commonly called 
autophagy is distinguished by the engulfment of cellular cytoplasm and organelles in a 
double membrane forming autophagosome [59]. The fusion of the autophagosome with the 
lysosome results in the degradation of cellular components such as abnormal proteins, 
cytoplasmic contents, and excess or damaged organelles by lysosomal enzymes. Autophagy 
is a dynamic cellular recycling system for producing the raw material in order to generate 
necessary energy for cell survival under stress and nutrient starvation situation. The process 
of autophagy consists of a sequence of steps including induction and initiation, vesicle 
formation and elongation, maturation, fusion with lysosome, degradation and release of the 
products into cytosol [60, 61]. Defects in autophagy may prevent cells from clearing 
unwanted invading protein aggregates and abnormal proteins, and thereby contribute to many 
disease and cancers. Many genes involved in autophagy, called autophagy-related genes 
(ATG) have been first reported in yeast, and then their orthologs in a variety of organisms 
were characterized and studied [62, 63]. The first ATG protein identified in yeast is a ser/thr 
kinase, ATG1, that binds to ATG13 and ATG17 to initiate autophagosome formation upon 
starvation [64]. The mammalian homologs of ATG1 and ATG17 are ULK1 and focal 
adhesion kinase family-interacting protein of 200 KD (FIP200), respectively [65]. Other 
proteins that are essential for autophagy are class III PI3K, and ATG6/Beclin1 (BECN1) that 
regulate the initiation of autophagy [66], ATG8/LC 3, and ATG12 that regulate 
autophagosome elongation [67], ATG9 and vacuole membrane protein 1 (VPM1). ATG9 
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may have a role in the delivery of membrane to the autophagosome [60, 68], and the 
interaction of BECN1 with VPM1 is required for autophagy [69]. Class I PI3K, unlike class 
III PI3K, indirectly regulates autophagy via AKT and mTORC1. mTOR kinase in the 
PI3K/mTOR signaling pathway is an important regulator that suppresses or activates 
autophagy. Many investigations indicated that in normal situation mTORC1 phosphorylates 
ULK1 and ATG13 by associating with the ULK1-ATG13-FIP200 complex, and inhibits 
autophagosome formation. Under nutrient deprivation and ATP deduction, AMP-dependent 
protein kinase (AMPK) is activated and phosphorylates tuberous sclerosis complex 2 (TSC2) 
and raptor, then inhibits mTORC1 mediated anabolic processes, and induces autophagy [60]. 
In addition to the involvement of autophagy in the homeostasis of the cells, there have been 
many studies indicating the role of autophagy in tumorigenesis [60, 70-73]. Autophagy acts 
as a double-edged sword in cancer [74]. Suppression of autophagy may have a role in the 
stimulation and initiation of cancers due to protein aggregation, oxidative stress, 
inflammation, genetic instability, and DNA damage [60]. Shreds of evidence from mouse 
models showed that suppression of autophagy in the liver and pancreas promotes tumor 
initiation [75, 76]. Although autophagy suppression has a role in cancer initiation, it has an 
important role in the promotion and growth of tumor cells, which enables them to overcome 
stress [77]. Many investigations in lung, pancreas, melanoma, and glioblastoma, colorectal, 
ovarian, and prostate cancers from the mouse models confirmed the essential role of 
autophagy in advanced cancers [60, 78]. Pieces of evidence illustrated that autophagy at a 
basal level can protect and promote cancer cells, but prevention or massive autophagy 
induction might inhibit carcinogenesis [71, 79, 80].  
 
PI3K/AKT pathway and susceptibility to infections  
Epstein-Barr virus (EBV) and Helicobacter pylori (H. pylori) are two well-known infections 
that contribute to gastric tumorigenesis [81-83]. EBV and H. pylori infections induce 
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inflammation-related genes that may hijack the host DNA methylation machinery by 
boosting DNA methyltransferases (DNMTs) to induce their replication [84-87].  Studies 
indicated that chronic inflammations triggered by H. pylori, and not H. pylori itself, are 
associated with the induction of aberrant DNA methylation. Also, some specific 
inflammation-related genes including CXCl2, IL1b, and NOS2 are involved in methylation 
induction via H. pylori. Suppression of inflammation by cyclosporin A treatment was shown 
to reduce the expression of these genes, and markedly repress methylation induction [88, 89]. 
Several studies demonstrated that H. pylori and EBV promote gastric epithelial cell 
proliferation through activating PI3K/AKT signaling pathway [90, 91]. H. pylori may 
enhance AKT and PDK1 interaction and increase AKT phosphorylation via the CagA 
virulence factor [92, 93]. In addition to CagA, VacA can also induce AKT and GSK3β 
phosphorylation, leading to PI3K/AKT signaling pathway activation [94]. Furthermore, 
herpesvirus families including EBV, HSV2, VZV, HCMV, and KSHV can modulate the 
PI3K/AKT pathway [95]. For instance, EBV through latent membrane proteins 1 (LMP1) and 
2 (LMP2A) can activate the PI3K/AKT signaling pathway [96-98]. Subsequently, AKT 
phosphorylation leads to downstream expression of NF-κB, which can trigger a cascade of 
pro-inflammatory responses that induce IL-1β and inducible nitric oxide synthase (iNOS) 
expression, as well as NO production in macrophages that show enhanced DNMT activity 
[92]. Tumor suppressor genes may be silenced epigenetically through hypermethylation of 
their promoter upon the hyperactivation of DNMTs. Furthermore, activated AKT is 
implicated in DNA damage responses and genome instability. Relatively, phosphorylation of 
the XRCC4-like factor by activated AKT accelerates its separation from DNA ligase 
IV/XRCC4 complex and promotes genomic instability [99]. Also, AKT by phosphorylating 
checkpoint kinase 1 (Chk1) or DNA topoisomerase 2-binding protein 1, and inhibiting 
replication protein A (RPA), breast cancer 1, and RAD51 recombinase, as double-strand 
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break resection factors, represses ATR/Chk1 signaling and homologous recombination repair, 
leading to genomic instability [98]. Figure 2 represents the PI3K/AKT pathway regulation by 
infectious proteins.  
 
Epigenetic regulation of the PI3K/AKT/mTOR pathway 
A growing body of evidence suggests that the aberrant gene expression pattern by epigenetic 
mechanisms may contribute to GC [100-108]. Epigenetic mechanisms are essential for proper 
gene expression and drive the regulation of several biological signaling pathways. Due to the 
important role of PI3K/AKT/mTOR signaling pathway in GC progression, the role of 
epigenetic regulation of this signaling pathway in GC development has been an interesting 
matter of research during the recent decade. Herein, we describe the defective 
PI3K/AKT/mTOR pathway genes deregulation by epigenetic mechanisms including 
promoter hypermethylation of TSGs, histone modifications, and their role in chromatin 
conformation, and non-coding RNAs modulation. 
Epigenetic modifications of tumor suppressor genes  
Epigenetic alterations in GC are as crucial in the regulation of PI3K/AKT/mTOR signaling 
pathway as the genetic ones. Phosphorylation and dephosphorylation of key components of 
the PI3K/AKT/mTOR pathway play a central role in controlling the activity of this pathway. 
DNA methylation is the most studied epigenetic mechanism, where a methyl group is added 
to the cytosine in the DNA sequence and regulates negatively gene expression [109]. 
Aberrant promoter hypermethylation was mostly reported in the tumor suppressor PTEN that 
regulates negatively the PI3K pathway and could be implicated in the development of GC 
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[110]. Besides, emerging evidence indicates that there are many TSGs which enable 
PI3K/AKT/mTOR pathway activation suppression, and regulate cell invasion, autophagy, 
and apoptosis in GC. TSGs inhibit PI3K/AKT/mTOR pathway by decreasing 
phosphorylation of key proteins or acting as the antagonist for this pathway. Therefore, 
aberrant hypermethylation of the promoter of TSGs followed by their silencing is important 
for aberrant PI3K pathway activation in GC. Figure 3 shows several TSGs that regulate 
PI3K/AKT/mTOR signaling pathway through promoter hypermethylation in GC. 
 
 
Histone modifications  
Histone modifications are serving as key components of epigenetic changes at the 
transcriptional level in GC. Histone acetylation and methylation are frequent phenomena that 
regulate gene expression during cancer progression by changing the chromatin conformation. 
The imbalance in histone acetylation/deacetylation is mediated by histone acetyltransferases 
(HATs) and histone deacetylase (HDAC) which are associated with gene transcription and 
silencing, respectively (Figure 4). Relatively, polypyrimidine tract binding protein 3 
(PTBP3), a differentiation regulator, which mediates apoptosis suppression and 5- 
fluorouracil resistance through HDAC6/AKT/TYMS axis is an important mediator during 
GC development. In PTBP3 knockdowns, protein phosphatase1 (PP1) dissociates from the 
HDAC6/PP1 complex and results in AKT dephosphorylation, which in turn causes lower 
expression of thymidylate synthase (TYMS), an essential gene in determining 5-FU 
resistance in tumor cells [111].  Additionally, aberrant histone methylation operates as a 
regulatory mechanism for many cancers. A cooperative role of PI3K/AKT and Wnt signaling 
to induce EMT through histone modifications was suggested. Inhibition of PI3K/AKT and 
Wnt/β-catenin signaling pathways by LY294002 and FH535, respectively showed that these 
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signaling pathways induce EMT progression in GC by regulating H3K27me3 and H3K27ac 
in the promoter of twist, a critical stimulator of EMT [112, 113]. Finally, lysine demethylase 
2B (KDM2B) and histone demethylase jarid1B (KDM5B) are two histone lysine demethylase 
of JHDM family that remove methyl residues from H3K4 and are able to promote cancer 
cells proliferation through AKT pathway by autophagy inhibition and EMT regulation, 
respectively [114, 115]. 
Non-coding RNAs  
Non-coding RNAs including miRNAs and lncRNAs function as regulators of the PI3K 
pathway, and may act as proto-oncogenes or TSGs. To date, multifarious non-coding RNAs 
have been explored to examine the post-transcriptional epigenetic signature of 
PI3K/AKT/mTOR pathway, and its impact on GC progression. 
MiRNAs  
Emerging evidence shows that miRNAs may act as tumor suppressors or oncogenes in GC. 
Upregulation of oncomiRs in GC represses the expression of TSGs which inhibit the growth, 
invasion, and metastasis, and induce apoptosis. For example, as an oncogene miRNA, miR-
21 expression increases in the poor prognostic tumor, and functions as an inhibitor of 
apoptosis and regulator of the cell cycle through p27 mTOR-mediated inhibition [116]. MiR-
21 is also involved in cisplatin (DDP) resistance by targeting PTEN [117]. It could trigger 
TGF-β1-induced EMT in GC cells by increasing PI3K/AKT expression [118]. In addition, 
miR-21 suppresses peroxisome proliferator-activated receptor α  (PPARα) expression to 
reduce its inhibitory effect on AKT activation [119]. Also, miR-21 mediates prostaglandin 
signaling by targeting 15-hydroxyprostaglandin dehydrogenase (15-PGDH), and leads to the 
accumulation of prostaglandin E2 (PGE2), and therefore to the stimulation of growth through 
PGE2/PI3K/AKT/Wnt/β-catenin axis [120]. Figure 5 indicates studied oncomiRs that 
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regulate PI3K/AKT/mTOR in GC. In contrast, decreased levels of tumor suppressor miRNAs 
in GC may induce the expression of oncogenes which promote cell growth and inhibit 
apoptosis. Accordingly, miR-34a is a well-known tumor inhibitor which is down-regulated in 
GC and helps to inhibit growth, invasion, and metastasis of GC by modulation of PI3K/AKT 
pathway. MiR-34a may contribute to attenuate platelet-derived growth factor receptor 
(PDGFR) and MET receptor tyrosine kinase expression which activate PI3K/AKT signaling 
cascade [121]. Furthermore, previous studies suggested that miR-34a suppresses EGFR 
signaling via downstream PI3K signaling to regulate matrix metalloproteinase-7 (MMP-7) 
expression, and inhibit invasion [122]. Other tumor suppressor miRNAs, including miR-497, 
miR-128, and miR-375 have been shown to be down-regulated in GC. MiR-497 targets RAF-
1 ser/thr kinase, and suppresses chemoresistance, cell proliferation, invasion, and metastasis 
through inhibition of the RAF1-MEK1-ERK/AKT axis. In GC, promoter hypermethylation of 
the mir-497 gene was found to be responsible for the downregulation of this miRNA [123]. In 
addition, miR-128 and miR-375 directly target PDK1 to inhibit AKT phosphorylation [124, 
125]. Figure 5 indicates studied tumor suppressor miRNAs that regulate PI3K/AKT/mTOR in 
GC. 
Long non-coding RNAs  
LncRNAs are non-protein coding transcripts with more than 200 nucleotides length, which 
play a role in cell differentiation, proliferation, and apoptosis. Furthermore, lncRNAs 
function as the regulator of the development and progression of cancer and participate in cell 
migration, invasion, and EMT. The major function of lncRNAs is sequestering miRNAs from 
their target mRNAs. LncRNAs contain miRNA binding sites and act as a negative regulator 
of miRNAs by sponging them. Furthermore, lncRNAs can bind proteins such as chromatin 
remodeling proteins or protein complexes to stabilize or recruit them to a specific DNA 
sequence. Concerning the critical functions of lncRNAs, they can regulate the main signaling 
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pathways in cells. Several lncRNAs have been reported to regulate GC development by 
modulating the AKT/PI3K pathway. Growth arrest-specific transcript 5 (GAS5), is a sponge 
regulator of miR-222 activity, leading to PTEN inhibition and AKT/mTOR signaling 
activation [126]. MiR-222 suppresses cyclin-dependent kinase inhibitor 1B (CDKN1B, 
p27Kip1) expression through activation of the PI3K pathway, and induces tumor development 
[127]. Also, HOX transcript antisense RNA (HOTAIR), a well-identified lncRNA, suppresses 
miR-34a expression, and up-regulates PI3K/AKT to render GC cells chemoresistant to 
cisplatin [128]. Furthermore, urothelial cancer-associated 1 (UCA1) lncRNA interacts with 
AKT to positively regulate GSK3β, mTOR, and PI3K signaling to promote GC cell 
proliferation, migration, and invasion [129, 130]. Increased level of the UCA1 in GC is 
associated with lymph node metastasis, staging,  and EMT [131]. LncRNAs that regulate 
PI3K/AKT/mTOR pathway in GC are shown in (Table 2). Recent surveys revealed the 
association of lncRNAs with polycomb repressive complex2 (PRC2), which has histone 
methyltransferase activity and induces the formation of H3K27me3, leading to repression of 
gene translation and alteration of drug resistance. UCA1, HOTAIR, and antisense non-coding 
RNA in the INK4 locus (ANRIL) are the well-defined lncRNAs that activate PI3K/AKT 
pathway through binding to PRC2 and altering gene expression [130, 132, 133]. Of note, 
Uc.160+ belongs to transcribed ultra-conserved regions (T-UCRs) lncRNAs family, which 
regulates PTEN expression and inhibits AKT phosphorylation. Uc.160+ is down-regulated in 
GC through hypermethylation of its promoter CpG islands [134] (Table 2). In addition, up-
regulation of the circular RNA ciRS-7 could promote PTEN/PI3K/AKT pathway by 





Table 2. Regulatory role of long non-coding RNAs in PI3K signaling in gastric cancer. 
LncRNAs which play a role in the activation of PI3K/AKT/mTOR: 
lncRNA 
 
Function in GC cells Potential mechanism Ref 
HOTAIR 
Cell proliferation, cell 
cycle progression, and 
apoptosis inhibition 
Acting as an endogenous sponge for miR-126 and 
activation of the VEGFA/PI3K/AKT/MRP1 axis [132] 
Multidrug resistance Knocking-down of HOTAIR leading to miR-34a up-regulation  [136] 
Cell progression 
Acting as an endogenous sponge for miR-618 and 
regulation of miR-618/KLF12 axis to upregulation of 
PI3K/AKT pathway 
[137] 
HAGLROS Cell progression and inhibition of autophagy 
Acting as an endogenous sponge for miR-100-5p and 
interacting with mTORC1 components to upregulation 
of mTOR expression 
[138] 
H19 Cell proliferation and invasion 
H19-derived miR-675 promotes AKT/mTOR pathway 
activation via downregulating RUNX1 [139] 
ANRIL 
(CDKN2B-AS1) 
Cell viability, migration, 
invasion, and cell 
apoptosis inhibition 
Knocking-down ANRIL leads to down-regulation of 
BMI1 via up-regulation of miR-99a [140] 
Cell proliferation Trans-acting repression of miR-99a/miR-449a to activate mTOR and CDK6/E2F1 pathway [133] 
AFAP1-AS1 Cell proliferation and cell apoptosis inhibition 
Knocking-down of AFAP1-AS1 leads to up-regulation 
of PTEN and a decreases the level of p-AKT protein [141] 
PVT1 
Multidrug resistance and 
cell apoptosis inhibition 
Up-regulation of the multidrug-resistant related genes 
including mTOR [142] 
UCA1 
Cell proliferation and cell 
cycle progression 
Induction of EZH2 and p-AKT to up-regulate cyclin 
D1 expression via AKT/GSK-3B/cyclin D1 axis 
[143] 
Cell proliferation, 
migration, invasion, and 
cell apoptosis inhibition 
Activation of PI3K/Akt/mTOR signaling pathway 
through up-regulation of AKT3, p-AKT3, p-mTOR, 
and S6K expression, and inhibition of EIF4E 
expression 
[144] 
Multidrug resistance and 
cell apoptosis inhibition Induction of EZH2 to activate PI3K/AKT pathway [145] 
Cell viability, migration, 
invasion, and cell 
apoptosis 
Activation of PI3K/AKT/GSK3β and NF‐κB signaling 
pathways via UCA1/miR‐182/TIMP2 axis [146] 
Linc-GPR65-1 Cell proliferation, EMT, migration, and invasion 
Up-regulation of the slug expression, a key mediator of 
EMT, through PTEN-AKT-slug signaling pathway [147] 
CRNDE Cell proliferation, Knocking-down of CRNDE leads to PTEN up- [148] 
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migration, and invasion regulation and decreases p-AKT and p-PI3K levels 
AK023391 
Cell proliferation, 
migration, invasion, cell 
cycle progression, and 
apoptosis 
Increases p-PI3K and p-AKT levels  [149] 
Linc00152 Cell proliferation and 
tumor growth 
Activation of PI3K/AKT signaling by direct binding 
with EGFR and constitutive activation of EGFR 
signaling 
[150] 
AC093818.1 Cell migration, and 
invasion 
Up-regulation of PDK1 by recruiting STAT3 and SP1 
to the PDK1 promoter region, and increase of PDK1, p-
AKT1, and p-mTOR levels 
[151] 
CCAT2 
Cell proliferation and 
inhibition of cell 
apoptosis inhibition and 
autophagy 
Increasing the levels of PI3K and mTOR proteins [152] 
Cell proliferation, 
viability, migration, 
invasion, inhibition of 
apoptosis and autophagy 
Silencing of CCAT2 leads to down-regulation of AKT 
and mTOR 
[153] 
EGFR-AS1 Cell proliferation Knocking-down EGFR-AS1 leads to down-regulation 
of EGFR and EGFR-dependent PI3K/AKT pathway 
[154] 
FOXD1-AS1 
Cell proliferation, tumor 
growth, motility, 
metastasis, and multidrug 
resistance 





migration and invasion, 
and inhibition of cell 
apoptosis 
Silencing of lncRNA-HCG18 leads to down-regulation 




Cell migration, invasion, 
and metastasis 
Acting as an endogenous sponge for miR-30b-3p and 
down-regulation of its target, PIK3CD, to upregulation 





invasion, EMT, cell cycle 
progression, and 
apoptosis 
Increasing PI3K and AKT proteins levels  [158] 
MALAT1 
Cell proliferation and 
apoptosis inhibition 
Knocking-down MALAT1 leads to up-regulation of 
miR-181a-5p and down-regulation of PI3K pathway 
via the MALAT1/miR-181a-5p/AKT3 axis 
[159] 
Cell proliferation, 
migration, invasion, and 
multidrug resistance 
Knocking-down MALAT1 leads to down-regulation of 




NEAT1 Cell viability and 
migration Increasing PI3K and AKT proteins levels  
[161] 
NORAD Cell proliferation and 
apoptosis inhibition 
Suppressing the expression of miR-214 to activate 
AKT/mTOR signaling via miR-214/AKT/mTOR axis 
[162] 
OIP5-AS1 Cell proliferation and 
apoptosis inhibition 
Acting as an endogenous sponge for miR-367-3p and 
regulation of miR-367-3p/HMGA2 axis to upregulation 




migration, invasion, and 
inhibition of cell 
apoptosis inhibition 
Knocking-down SNHG12 leads to down-regulation of 
PI3K/AKT signaling pathway and decreases p-PI3K, 




Cell viability, migration, 
invasion, EMT, and 
inhibition of cell 
apoptosis 
Acting as an endogenous sponge for miR-145and 
regulation of miR-145/SOX9 axis to upregulation of 
PI3K/AKT/mTOR pathway 
[165] 
SOX2OT Cell proliferation and 
metastasis 
Acting as an endogenous sponge for miR-194-5p and 
regulation of miR-194-5p/AKT2 axis to upregulation 





EMT, inhibition of cell 
apoptosis, and multidrug 
resistance 
Increasing PI3K, p-AKT, and p-mTOR proteins levels 
 
[167] 




Function in GC cells Potential mechanism Ref 
HOTAIRM1 Inhibition of cell 
progression 
Acting as an endogenous sponge for miR-17-5p and 
regulation of miR‐17‐5p/PTEN axis to suppression of 
the PI3K/AKT pathway 
[168] 
GAS5 
Inhibition of cell 
proliferation 
Acting as an endogenous sponge for miR-222 to 
suppression of the PTEN/AKT/mTOR pathway [169] 
 
Inhibition of cell 
proliferation, migration, 
and invasion, as well as 
cell apoptosis induction 
Acting as an endogenous sponge for miR-106a-5p to 
suppression of the AKT/mTOR pathway [170] 
ADAMTS9-AS2 
Inhibition of cell 
proliferation, EMT, 
migration, and invasion, 
as well as cell apoptosis 




CRAL Reversing cisplatin 
resistance 
Acting as an endogenous sponge for miR-505 to 




Inhibition of cell 
proliferation, tumor 
growth, metastasis, and 
cell cycle progression, as 
well as apoptosis 
induction 
Acting as an endogenous sponge for miR-19a‐3p to 




Inhibition of cell 
proliferation, and tumor 
growth, as well as cell 
apoptosis induction 
Acting as an endogenous sponge for miR-107 to 




Inhibition of cell 
proliferation and 
apoptosis induction 




Inhibition of cell 
proliferation, metastasis, 
as well as apoptosis 
induction 
Acting as an endogenous sponge for microRNA-425-
5p to regulate AKT expression and p53 signaling 
pathway (via the PTEN/Akt/MDM2/p53 axis) 
[176] 
LOC101928316 
Inhibition of cell 
proliferation, migration, 
invasion, and metastasis 
Silencing of LOC101928316 leads to an increase in 
AKT3, mTOR, and p‐mTOR levels as well as 
inhibiting the expression of PTEN 
[177] 
LINC01419 
Inhibition of cell 
proliferation, migration, 
invasion, and promotion 
of autophagy 
Suppression of PI3K/AKT1/mTOR pathway through a 
decrease in AKT1 and mTOR phosphorylation 
[178] 
TUBA4B 
Inhibition of cell 
proliferation, migration, 
invasion, metastasis, and 
induction of cell 
apoptosis 
Acting as an endogenous sponge for miR-214 and miR-
216a/b and up-regulation of their target, PTEN, to 
inactivate PI3K/AKT signaling pathway 
[179] 
STXBP5-AS1 
Inhibition of cell 
proliferation, migration, 
and invasion 
Down-regulation of PI3K/AKT signaling pathway and 






Epigenetics and chemoresistance 
Chemoresistance is an important problem that results in the failure of treatment.  It is well 
established that aberrant activation of the PI3K/AKT pathway may lead to chemoresistance 
through apoptosis inhibition, and cell survival promotion. Relatively, it was shown that the 
status of PTEN expression and AKT phosphorylation determine the susceptibility of 
endometrial cancer cells to chemotherapy. Strikingly, PTEN expressing patients undergoing 
chemotherapy treatment had significantly better survival rates in comparison with PTEN 
negative patients [181]. Also, it was shown that inducing PTEN expression chemically in 
cisplatin-resistant human ovarian cancer cells, can resensitize those cells and induce 
apoptosis [182]. Different studies indicated that inhibition of PI3K/AKT signaling by 
epigenetic approaches can enhance the chemosensitivity of cancer cells. Correspondingly, 
miR-214, miR-221, and mir-222 were shown to have an important role in cisplatin resistance 
by targeting PTEN [183-185]. Moreover, lncRNA regulator of AKT signaling associated with 
HCC and RCC (lncARSR) and miRNA-130b contributed to chemosensitivity to doxorubicin 
and adriamycin, respectively via the PI3K/AKT pathway [186, 187]. Particularly, miR-19a/b, 
miR-21, and miR-106a have been shown to be significantly upregulated in multidrug-
resistant GC cell lines. Interestingly, enforced expression of these miRNAs significantly 
increased sensitivity to cisplatin, 5-FU, and adriamycin by targeting PTEN [117, 188, 189]. 
Therefore, the PI3K/AKT pathway inactivation via epigenetic approaches may help to 
overcome therapeutic resistance.  
 
Targeting PI3K/AKT/mTOR pathway for gastric cancer treatment     
As an important pathway that regulates cell growth, metabolism, survival, and resistance to 
chemotherapy, targeting and inhibiting the PI3K pathway may be a potential therapeutic 
approach for patients with GC [190]. Targeted therapy with many preclinical and clinical 
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studies is common and a highly effective strategy in GC treatment [191]. Targeted therapy 
against the PI3K pathway may be an important strategy in the treatment of GC. Therapeutic 
targeting of the PI3K pathway mostly consists of using PI3K, AKT, and mTOR inhibitors as 
well as dual mTOR1/mTOR2 and PI3K/mTOR inhibitors.  
 
PI3K inhibitors 
PI3K has been the primary target for the development of PI3K/AKT/mTOR signaling 
pathway inhibitors. PI3K inhibition prevents the downstream activation of AKT and mTOR, 
leading to repression of those genes associated with cancer cell survival and tumor 
progression. A number of drugs are being developed to inhibit PI3K, and clinical trials have 
demonstrated that some of these may exert beneficial effects as anticancer agents. Copanlisib 
is an FDA approved (September 2017) drug against PI3K-α and PI3K-δ for the treatment of 
patients with relapsed follicular lymphoma [192]. Isoform-specific PI3K inhibitors and pan-
PI3K inhibitors are two classes of PI3K inhibitors. LY294002, a quercetin analog, is a 
specific PI3K inhibitor that significantly reduces GC tumor growth. LY294002 acts as a 
reversible inhibitor of PI3K that can trigger apoptosis in GC through upregulating cleaved-
PARP, cleaved-caspase-3, p53, p53 upregulated modulator of apoptosis (PUMA) as well as 
downregulating MMP-2, MMP-9, and pyruvate kinase M2 (PKM2) [193-196]. The 
combination of LY294002 with cecropinXJ, a cationic antimicrobial peptide, has 
synergistically induced apoptosis of GC cells by suppressing the expression of BCL2 family 
proteins [197]. Cai et al. [198] demonstrated that poly (lactic acid/glycolic) (PLGA) 
nanoparticles loaded with LY294002 and docetaxel are beneficial in chemo-targeted therapy 
of GC. The drug delivery system led to the suppression of proliferation as well as the 
induction of apoptosis at gastric tumor sites both in vivo and in vitro. 
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BKM120, a pan-class I PI3K inhibitor, alone and in combination with other drugs, has 
successfully entered phase II and III clinical trials in the treatment of triple-negative 
metastatic breast cancer (NCT01629615), recurrent glioblastoma (NCT01870726), metastatic 
castration-resistant prostate cancer (NCT01634061) and GC (NCT01576666). Additionally, 
BKM120 in combination with fulvestrant and paclitaxel reached phase III clinical trial on 
patients with metastatic breast cancer (NCT01633060, NCT01572727). Although the number 
of anticancer drugs entering clinical trials in all stages of development is limited, clinical 
studies in GC are still ongoing. Yang et al. [199] indicated that combination therapy using 
BKM120 and olaparib (a poly ADP ribose polymerase (PARP) inhibitor) shows improved 
effectiveness and a synergism against AT-rich interaction domain 1A (ARID1A)-deficient 
GC cells, a member of the SWI/SNF chromatin-remodeling complex. Besides, a combination 
of alpelisib (BYL719), an ATP-competitive p110α-specific inhibitor, and taxol (paclitaxel) a 
microtubule inhibitor, synergistically repressed PI3K pathway genes and induced apoptosis in 
PIK3CA mutant GC models in vitro and in vivo [200]. In phase I clinical trial, BKM120 was 
used in combination with LDE225 to determine the maximum dose that can be safely given 
together to patients with advanced solid tumors including metastatic breast cancer, advanced 
pancreatic adenocarcinoma, metastatic colorectal cancer, recurrent glioblastoma multiform, 
gastroesophageal junction cancer, triple-negative metastatic breast cancer, hormone receptor-
positive (ER+/PR+, and Her2-) metastatic breast cancer, and GC (NCT01576666). A phase I 
clinical trial, where BYL719 in combination with AUY922 (an HSP90 inhibitor) was studied 
on patients with advanced GC or metastatic GC harboring molecular alterations of PIK3CA 
or HER2 amplification is completed (NCT01613950).  
Moreover, the study of AZD5363 in combination with paclitaxel successfully entered phase 
II clinical trial in advanced gastric adenocarcinoma patients carrying either a mutation and/or 
PIK3CA amplification. GSK2636771 has been used for targeted therapy in combination with 
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paclitaxel in phase I/II clinical trials to treat PTEN-deficient patients with advanced gastric 
adenocarcinoma (NCT02451956). Table 3 summarizes PI3K inhibitor drugs and the clinical 
trial status of these compounds.  
 
AKT inhibitors 
AKT has a central role, and its function leads to potent activation of the PI3K pathway. There 
are three AKT isoforms including AKT1, AKT 2, and AKT3 with 80% amino acid sequence 
identity. AKT inhibitors are classified into two classes, ATP competitive inhibitors, and 
allosteric inhibitors. Allosteric inhibitors repress the localization of AKTs into the plasma 
membrane while ATP competitive inhibitors block their kinase activity. Several different 
types of AKT inhibitors have also been tested against various tumor types in preclinical as 
well as clinical trials. NL-71-101, ATP-competitive inhibitors, were the first AKT inhibitors 
that were shown to promote apoptosis in ovarian cancer cells [201]. GSK690693 is another 
ATP-competitive inhibitor that inhibits all the isoforms of AKT. Lee et al. [202] reported that 
ARID1A-knockdown GC cells treated with GSK690693 showed increased apoptosis. MK-
2206 is an AKT inhibitor that can reduce p-AKT Thr308 and p-AKT Ser473 level, and 
decrease phosphorylation of downstream target genes like GSK-3β, proline-rich AKT 
substrate 40 kDa (PRAS40), FoxO1/FoxO3a, and BAD [203, 204]. Studies indicated that 
MK-2206 positively synergies other drugs such as 5-fluorouracil, doxorubicin, curcuminoid 
EF24, carboplatinum, paclitaxel, and cisplatin, and enhances chemosensitivity and apoptosis 
in GC [205-208]. MK-2206 is used in clinical trials for gastric and gastroesophageal cancer 
treatment (NCT01260701, NCT01705340). In addition, ipatasertib (GDC-0068), a pan-AKT 
inhibitor, has used in combination with mFOLFOX6 in a randomized phase II clinical trial to 
treat patients with metastatic gastric or gastroesophageal junction cancer and results indicated 
no difference between ipatasertib/ mFOLFOX6 and placebo/ mFOLFOX6 (NCT01896531) 
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treatments [209]. Perifosine, called also KRX-0401, was shown to inhibit GC cell growth 
through the reduction of total-eIF4E and phosphorylated-eIF4E levels as downstream 
effectors of the AKT/mTOR pathway [210]. In phase III clinical trial for multiple myeloma 
and colon cancer treatment, it was discontinued in 2012, and 2013, respectively, as it failed to 
improve overall survival in comparison with capecitabine, a chemotherapy drug. 
As an AKT inhibitor, AZD5363 binds and inhibits all isoforms of AKT and has a high effect 
on tumor growth inhibition in cancer cells [211, 212]. The combination of AZD5363 and 
paclitaxel has studied in phase II clinical trial for the treatment of patients with advanced 
gastric adenocarcinoma harboring PI3KCA mutation or amplification (NCT02451956). Table 
4 summarizes AKT inhibitor drugs that entered the clinical trial phase. 
 
mTOR inhibitors 
mTOR is the terminal effector of the PI3K/AKT/mTOR signaling pathway, and can also be 
activated independently from AKT. mTOR was classified into two distinct multi-protein 
complexes; mTORC1 and mTORC2. mTORC1 is composed of mTOR, raptor (regulatory 
associated protein of mTOR), MLST8 (mammalian lethal with Sec13 protein 8), PRAS40, 
and DEPTOR (death domain-containing mTOR interacting protein). mTORC1 promotes 
protein synthesis by phosphorylating EIF4EBP1, RPS6KB1, and RPS6KB2 [213, 214]. 
mTORC2 is composed of mTOR, MSIN1 (mammalian stress-activated protein kinase 
(SAPK) interacting protein 1), PROTOR (protein observed with RICTOR), RICTOR 
(rapamycin-insensitive companion of mTOR), MLST8, and DEPTOR [214].  mTORC2 
phosphorylates AKT at Ser473, making, therefore, this protein kinase fully active [215]. 
mTOR through increasing the expression of nutrient transporter proteins, HIF-1/HIF- 2, and 
anti-apoptotic proteins play a key role in cell metabolism, angiogenesis, and cell survival, 
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respectively [216]. Thus, it was thought that selective mTOR inhibitors would be more 
effective for cancer treatment. Several rapamycin derivatives are under preclinical and 
clinical studies for cancer treatment. The first generations of mTOR inhibitors were 
rapamycin and its analogs (rapalogs), temsirolimus (CCI-779), and everolimus (RAD001). 
Rapamycin is an antifungal metabolite isolated from Streptomyces hygroscopicus that binds 
to FK506-binding protein 12 (FKBP12), and this complex inhibits the activity of mTORC1 
by directly blocking substrate recruitment through reducing access to the active site [217]. 
Temsirolimus (CCI-779) is the first generation of mTOR inhibitors created by Wyeth 
Pharmaceuticals that bind to FKBP12 to prevent mTORC1 activity. It was approved by the 
FDA in May 2007 for the treatment of renal cell carcinoma [218]. Currently, it is being tested 
in phase I trials for advanced solid tumors and GC [219]. Everolimus is a rapamycin 
derivative developed by Novartis that binds directly to mTORC1 to prevent signaling 
activation. It was approved by the FDA in March 2009 as the first mTOR inhibitor drug for 
the treatment of patients with advanced kidney cancer after failure of either sunitinib or 
sorafenib standard therapy and was FDA approved in Feb 2016 for progressive, 
nonfunctional gastrointestinal and lung neuroendocrine tumors. Everolimus alone and in 
combination with capecitabine and oxaliplatin is currently being used in phase I and phase II 
clinical trials to treat patients with GC. Inhibition of mTORC1 alone via the first generation 
of mTOR inhibitors leads to MAPK pathway activation through PI3K-dependent feedback 
[220]. Thus, second-generation mTOR inhibitors were developed against both mTORC1 and 
mTORC2. AZD8055 is a second-generation mTOR inhibitor that suppresses invasion and 
migration of trastuzumab-resistant HER-positive gastric cancer cells through deactivating 
PI3K/AKT/mTOR pathway [221]. AZD2014 is used as second-line chemotherapy in phase II 
trials for TSC1/2 mutated or TSC1/2 null GC patients (NCT03082833). RICTOR knockdown 
reversed the inhibitory effect of AZD2014 in the treatment of RICTOR-amplified patient-
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derived GC cell lines [222]. Currently, several dual mTORC1/2 inhibitors are under clinical 




It has been shown that PI3k/AKT/mTOR signaling pathway is highly complex and is an 
important player in GC. Aberrant activation of this pathway induces cell survival and 
metastasis, and can also lead to cancer cells to escape from apoptosis through dysregulation 
of anti and pro-apoptotic genes. In addition, PI3K/AKT/mTOR possesses a central role in 
EMT promotion and chemoresistance. Studies have shown that aberrant activation of this 
pathway results from amplification or mutation in PI3K, AKT, or PTEN. However, it is 
evident that abnormal PI3K/AKT/mTOR activation cannot be attributed to genetic changes 
alone, but also epigenetic modifications play a crucial role in regulating PI3K/AKT/mTOR 
pathway, and function as key factors in GC development. Promoter hypermethylation of 
negative regulators of PI3K/AKT/mTOR pathway like PTEN and other TSGs as well as 
histone modifications and non-coding RNAs (miRNAs and lncRNAs) modulations play a 
central role in aberrant activation of this pathway. Unlike genetic mutations, epigenetic 
changes are generally reversible. Therefore, epigenetic restoration may provide opportunities 
for designing new anticancer drugs. Moro et al. indicated that treating GC cell lines with 5-
aza-2′-deoxycytidine (5-aza-dC) as hypomethylating agent improves the sensitivity of GC 
cells to cytotoxic drugs [223]. Additionally, cancer associated fibroblasts, as one of the most 
abundant cell types in GC play important roles in gastric carcinogenesis, and their behaviors 
is regulated by epigenetic mechanism [224]. Correspondingly, using epigenetic inhibitors 
such as DNMT inhibitors (DNMTis), antagomirs, small interfering RNA (siRNA), and 
CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats-CRISPR associated 
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nuclease 9) system [87] in combination with targeted agents or chemotherapy drugs may help 
to improve synergistically clinical benefits in GC treatment.  
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Figure 1. Overview of PI3K/Akt/mTOR signaling pathway in cancer development. 4E-BP1: Eukaryotic 
translation initiation factor 4E-binding protein 1; AKT: Protein kinase B; BAD: Bcl-2-associated death 
promoter; Bcl-xl: B-cell lymphoma-extra large; CASP9 : caspase-9; EGF: Epidermal growth factor; EMT: 
epithelial–mesenchymal transition; FOXO: Forkhead box protein; GSK3B: Glycogen synthase kinase 3 beta; 
IGF: Insulin-like growth factor; MDM2: Mouse double minute 2; mTORC1: Mammalian target of rapamycin 
complex 1; mTORC2: Mammalian target of rapamycin complex 2; NF-KB: nuclear factor kappa B; PDGF: 
Platelet-derived growth factor; PDK1: Phosphoinositide-dependent kinase-1; PI3K: Phosphatidylinositol-4,5-
bisphosphate 3-kinase; PIP2: Phosphatidylinositol 4,5-bisphosphate; PIP3: Phosphatidylinositol (3,4,5)-
trisphosphate; PTEN: Phosphatase and tensin homolog; S6K: ribosomal protein S6 kinase; Slug: Zinc finger 
protein SNAI2; Snail: Zinc finger protein SNAI1; TSC: Tuberous sclerosis; TGF-B: Transforming growth 
factor beta; TWIST: Twist-related protein. 
 
 
Figure 2. PI3K/AKT pathway regulation by infection proteins. NF-kB: Nuclear factor kappa B; 
AKT: Protein kinase B; XRCC4: X-Ray Repair Cross Complementing 4; DNMT: DNA methyltransferase: 
Chk1: checkpoint kinase 1; RAD 51: RAD51 recombinase; TopBP1: DNA topoisomerase 2-binding protein 1; 
BRCA 1: BRCA1 DNA repair associated; RPA: Replication protein A; ATR: ataxia telangiectasia and Rad3-
related protein. 
 
Figure 3. Promoter methylation in tumor suppressor genes triggers gastric cancer by activation of 
PI3K/AKT/mTOR. ADAMTS9: a disintegrin-like and metalloprotease with thrombospondin type 1 motif 9; 
CHRDL1: chordin-like 1; EMT: epithelial-mesenchymal transition; FBP2: fructose-1,6-bisphosphatase-2; 
PTEN: phosphatase and tensin homolog; REG1A: regenerating protein 1 alpha; ROR2: receptor tyrosine kinase 




Figure 4. Gene activation and repression by histone acetylation and deacetylation.  
 
 
Figure 5. Involvement of non-coding RNAs contributes to the progression of gastric cancer by regulation 
of the PI3K/Akt/mTOR signaling pathway.  OncomiRs, tumor suppressor miRNAs, and lncRNAs are 
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represented in red, green, and black color, respectively. MiRNAs and lncRNAs having direct effect on 
PI3K/AKT/mTOR are underlined. LncRNAs that sponge miRNAs are represented in bold. 
 
 
 
 
 
 
 
 
